Top 10 Best Biomarker Testing Services of 2026

Eurofins Scientific stands out for scaling biomarker testing across regulated clinical and life science workflows using large laboratory networks. Core capabilities include biomarker assay development, clinical validation support, and high-throughput laboratory execution for research and clinical programs. The provider supports sample handling, QA documentation, and result reporting designed for traceability from specimen receipt through assay readout. Eurofins also offers complementary expertise across genomics, proteomics, and immunoassays to match biomarker type to assay strategy.

Charles River Laboratories stands out for delivering biomarker testing through a global network that supports study execution from assay development through sample testing. Its core biomarker testing capabilities include immunoassay and bioanalytical workflows tied to translational research needs and regulatory-grade study conduct. Strong operational integration with safety and toxicology services helps teams connect biomarker readouts to dose, exposure, and phenotyping across study phases. Delivery quality is geared toward structured project management and documented lab practices suitable for decision-making in development programs.

Labcorp Drug Development stands out with integrated biomarker testing plus clinical research operations that support study execution from sample receipt through reporting. Its core capabilities cover central laboratory drug development testing, companion diagnostic workflows, and biomarker assays used in oncology trials. The organization also supports regulatory-facing documentation that helps teams manage traceability and quality expectations across studies. Delivery quality is strengthened by standardized lab processes designed for multi-site clinical programs.

IQVIA stands out for delivering end-to-end biomarker testing programs that connect laboratory operations with clinical and regulatory workflows. The provider supports assay and biomarker strategy, diagnostic testing execution, and data management designed for trial and real-world evidence needs. Delivery is strengthened by broad biopharma engagement experience and standardized processes that help integrate biomarker results into study reporting. Execution depth is strongest when projects need tight coordination across sites, labs, and downstream data systems.

Syneos Health stands out for combining biomarker testing execution with clinical development and regulatory-facing execution services through a single global services organization. It supports biomarker strategy and companion diagnostics oriented workflows alongside laboratory and diagnostic operations for clinical studies. The provider also integrates data, specimen handling requirements, and study documentation to reduce handoff friction between lab execution and clinical teams. Strong alignment exists for oncology and other biomarker-driven indications where repeatable assay workflows and protocol-grade quality systems matter.

CROMSOURCE stands out for pairing laboratory biomarker testing with a managed, end-to-end operational model that supports sample handling and reporting workflows. The core capabilities focus on cancer-relevant biomarker testing, test interpretation support, and delivery of lab outputs designed for clinical decision use. CROMSOURCE also emphasizes documentation, chain-of-custody style handling, and quality controls that help teams operationalize biomarker programs across sites. This provider fits organizations that need consistent testing execution and structured result turnaround rather than only raw assay work.

Synlab stands out with centralized laboratory operations and multi-country clinical infrastructure that supports high-throughput biomarker workflows. It offers biomarker testing services spanning oncology, infectious disease diagnostics, and therapeutic monitoring activities that rely on standardized lab processes. The delivery model emphasizes validated analytical methods, sample tracking, and reporting designed for clinical decision support. Service scope remains broad, but less clearly tailored for niche assay development requests compared with boutique method-design providers.

F. Hoffmann-La Roche stands out for biomarker testing depth tied to large-scale translational research and oncology development. The provider supports companion diagnostic development workflows, including biomarker assay design, analytical validation, and study-ready testing enablement. Delivery emphasizes regulated quality processes, reproducibility controls, and documented assay performance for clinical decision use cases. Strong integration between assay strategy and clinical evidence generation supports teams needing end-to-end biomarker-to-therapy linkage.

AbbVie stands out as a large biopharmaceutical company with deep experience translating biomarkers into clinical development programs. Its biomarker testing footprint is typically anchored to trial support, companion diagnostic strategy, and data integration needs across oncology and immunology. Strength is aligned with complex study requirements where assay selection, regulatory-aligned workflows, and quality controls matter. Engagement is best when biomarker testing outcomes feed directly into decision-making for drug development and associated diagnostics.

AstraZeneca stands out as a biomarker-driven pharmaceutical developer with deep translational experience across oncology and other therapeutic areas. Core support centers on biomarker discovery, assay strategy alignment, and clinical validation through sponsor-led studies tied to drug development decisions. The organization’s biomarker activity is often embedded in study design and regulatory-grade evidence generation rather than standalone laboratory operations for external customers. External teams can benefit most when their biomarker questions map directly to AstraZeneca’s clinical programs and companion diagnostic needs.